X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES LUPIN LTD VENUS REMEDIES/
LUPIN LTD
 
P/E (TTM) x -681.0 20.1 - View Chart
P/BV x 0.2 2.7 7.3% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   LUPIN LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
LUPIN LTD
Mar-17
VENUS REMEDIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2181,750 12.5%   
Low Rs821,384 5.9%   
Sales per share (Unadj.) Rs365.6387.4 94.4%  
Earnings per share (Unadj.) Rs1.556.6 2.6%  
Cash flow per share (Unadj.) Rs37.976.8 49.4%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs382.5298.9 128.0%  
Shares outstanding (eoy) m11.44451.58 2.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x0.44.0 10.1%   
Avg P/E ratio x101.027.7 365.0%  
P/CF ratio (eoy) x4.020.4 19.4%  
Price / Book Value ratio x0.45.2 7.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m1,717707,513 0.2%   
No. of employees `0001.016.8 6.1%   
Total wages/salary Rs m32428,495 1.1%   
Avg. sales/employee Rs Th4,100.710,418.3 39.4%   
Avg. wages/employee Rs Th318.01,697.0 18.7%   
Avg. net profit/employee Rs Th16.71,523.0 1.1%   
INCOME DATA
Net Sales Rs m4,183174,943 2.4%  
Other income Rs m201,065 1.9%   
Total revenues Rs m4,203176,008 2.4%   
Gross profit Rs m81244,931 1.8%  
Depreciation Rs m4179,122 4.6%   
Interest Rs m3801,525 24.9%   
Profit before tax Rs m3535,349 0.1%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m189,785 0.2%   
Profit after tax Rs m1725,575 0.1%  
Gross profit margin %19.425.7 75.5%  
Effective tax rate %51.627.7 186.3%   
Net profit margin %0.414.6 2.8%  
BALANCE SHEET DATA
Current assets Rs m2,771119,542 2.3%   
Current liabilities Rs m1,93161,206 3.2%   
Net working cap to sales %20.133.3 60.2%  
Current ratio x1.42.0 73.5%  
Inventory Days Days12576 164.5%  
Debtors Days Days5490 59.8%  
Net fixed assets Rs m5,328131,660 4.0%   
Share capital Rs m114903 12.7%   
"Free" reserves Rs m4,177134,073 3.1%   
Net worth Rs m4,376134,976 3.2%   
Long term debt Rs m1,91156,478 3.4%   
Total assets Rs m8,428266,073 3.2%  
Interest coverage x1.124.2 4.5%   
Debt to equity ratio x0.40.4 104.3%  
Sales to assets ratio x0.50.7 75.5%   
Return on assets %4.710.2 46.2%  
Return on equity %0.418.9 2.1%  
Return on capital %6.619.3 34.3%  
Exports to sales %00-   
Imports to sales %20.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m858NA-   
Fx inflow Rs m081,885 0.0%   
Fx outflow Rs m85821,506 4.0%   
Net fx Rs m-85860,378 -1.4%   
CASH FLOW
From Operations Rs m46941,148 1.1%  
From Investments Rs m29-25,287 -0.1%  
From Financial Activity Rs m-4644,332 -10.7%  
Net Cashflow Rs m3520,193 0.2%  

Share Holding

Indian Promoters % 32.9 46.6 70.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 31.9 1.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.1 657.4%  
Shareholders   20,121 98,259 20.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 20, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - J.B.CHEMICALS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS